Unpacking mAb Manufacturing Purification Challenges

By Brian O’Mara, VP Process Sciences

Although cell and gene therapies and antibody-drug conjugates (ADCs) are currently dominating the headlines, monoclonal antibodies (mAbs) remain the largest class of biopharmaceuticals. The market share of mAbs continues to expand, with projections indicating double-digit growth from 2023 to 2030. As these drug products increase in complexity to treat more diseases, new and innovative purification methods and technologies are being developed.

In a recent webinar, three experts in mAbs discussed the challenges and solutions of purification. Hear the perspectives of panelists Brian O’Mara, Vice President of Process Sciences at Scorpius BioManufacturing, Buzz Lobbezoo, senior field application specialist at Thermo Fisher Scientific, and Angela Lewandowski, senior director of Downstream Bioprocess Development at BMS, on the downstream processing of mAbs. Learn about controlling heterogeneity, solving for post-translational structural complexities, ensuring mAb stability, replacing an affinity capture step when protein A fails, viral clearance, regulatory considerations, the future of downstream purification of therapeutic antibodies, and more.